Allergy Therapeutics plc (LON:AGY – Get Free Report) reached a new 52-week low during trading on Friday. The stock traded as low as GBX 1.10 and last traded at GBX 1.13, with a volume of 30,373,307 shares. The stock had previously closed at GBX 1.23.
Allergy Therapeutics Stock Performance
The firm has a fifty day moving average price of GBX 3.73 and a 200 day moving average price of GBX 7.33. The company has a current ratio of 2.29, a quick ratio of 1.48 and a debt-to-equity ratio of -646.31. The firm has a market cap of £71.30 million, a PE ratio of -1.16, a price-to-earnings-growth ratio of -30.70 and a beta of 0.83.
Allergy Therapeutics Company Profile
Allergy Therapeutics is an international commercial biotechnology company focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development include vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development.
Further Reading
- Five stocks we like better than Allergy Therapeutics
- ZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in Limbo
- Owens Corning’s Stock Slump May Have a Silver Lining for Dividend Investors
- The Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity Stocks
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
Receive News & Ratings for Allergy Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergy Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
